| 영문 | stool guaiac test | 한글 | 대변 구아이악 검사 |
|---|---|---|---|
| 설명 | 대변내에 있을 수 있는 잠혈(눈에 보이지 않는 출혈)유무를 검사하는 방법으로, 혈구내의 heme peroxidase에 의해 guaiac이 산화되는 반응을 이용하여 측정한다. 방법은 3일간에 걸쳐 한 변에서 2군데씩 채취하여 검사한다. 위양성 반응(거짓으로 혈액이 있다고 나타나는 반응)은 식물 과산화효소를 함유하고 있는 홍당무의 섭취나 혈구 성분을 함유하고 있는 고기 섭취 등에서 나타날 수 있으며, 위음성 반응(실제로 혈액은 있지만, 혈액이 없다고 나타나는 반응)은 환원력을 가지고 있는 비타민 C의 복용시 나타날 수 있다. 특히 위양성 반응이 매우 흔하다. |
||
| 영문 | Rorschach Test | 한글 | 로르샤하 검사 |
|---|---|---|---|
| 설명 | 사고장애와 정서장애에 민감한 투사검사(projective test). 검은색과 몇가지 색으로 이루어진 잉크얼룩같은 도형이 그려진 10개의 카드를 이용한다. 피검자에게 카드를 보이고 본 것에 대해 말하도록 한다. 다음에는 얼룩의 어느 위치가 피검자가 말한 지각대상을 암시하는지 찾도록 한다. 피검자의 답변을 분석하면 그의 사고와 정서상태에 대한 정보를 얻을 수 있다. |
||
| 영문 | Mantoux test | 한글 | 망토우검사 |
|---|---|---|---|
| 설명 | 소아에 주로 실시하는 검사 방법으로, BCG접종후에나 혹은 결핵균에 한번이라도 노출된 경우에 양성반응으로 나온다. 우리나라에서는 생후 1개월에 BCG예방접종을 시행하므로 대부분 양성으로 나오게 되나, 이 예방접종을 받지 않은 상태에서 양성으로 나오면, 결핵균의 침투를 의심할 수 있다. |
||
| 영문 | stress test | 한글 | 스트레스 검사 |
|---|---|---|---|
| 설명 | 협심증이 일어나기 쉬운 환자에게서 그 정도를 판단하기위해 시행한다. 방법은 같은 곳에서 환자를 달리도록 한 다음, 얼마의 속도에서 혈압이 떨어지고 협심증 증상이 나타나는가를 검사한다. 대개 심할수록 낮은 속도에서도 증상이 빨리 나타난다. |
||
| 영문 | visual field test | 한글 | 시야검사 |
|---|---|---|---|
| 설명 | 눈을 한곳에 고정시킨 채, 관찰할 수 있는 주변공간을 시야라 한다. 시야를 검사하는 가장 간단한 방법은 대면검사(confronting test)이다. 이것은 피검사자의 눈을 검사자의 눈에 맞추어 보도록 하여 눈을 고정시킨채, 검사자가 손가락끝을 위쪽, 아래쪽, 왼쪽, 오른쪽, 그리고 비스듬히 경사진 곳 등으로 옮겨보아 피검사자가 관찰할 수 있는지 여부를 정하는 검사법이다. 이보다 정확한 검사법은 자동식 컴퓨터시야검사법이 있다. 대개, 눈자체의 이상이 있어도 시야검사에서 이상이 나오지만, 이외 뇌의 이상으로 시각의 형성경로에 이상이 있어도 역시 이상소견을 보인다. |
||
| AMA | against medical advice; alkaline membrane assay; American Management Association; American Medical A... |
|---|---|
| NA | Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida... |
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| TAT | tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex... |
| AUDIT | alcohol use disorders identification test |
| antibody | An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc. (18 Nov 1997) |
|---|---|
| antibody affinity | A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. (12 Dec 1998) |
| antibody aldolase | <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations Registry number: EC 4.1.2.- Synonym: fab 33f12, aldolase catalytic antibody (26 Jun 1999) |
| antibody combining site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antibody deficiency disease | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody deficiency syndrome | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
| antibody-dependent enhancement | Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors. (12 Dec 1998) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
| antibody diversity | The phenomenon of immense variability characteristic of antibodies, which enables the immune system to react specifically against the essentially unlimited kinds of antigens it encounters. Antibody diversity is accounted for by three main theories: 1) the germ line theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; 2) the somatic mutation theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and 3) the gene rearrangement theory, which holds that antibody diversity is generated by the rearrangement of variable region gene segments during the differentiation of the antibody-producing cells. (12 Dec 1998) |
| antibody excess | In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present. (05 Mar 2000) |
| antibody-forming cell | <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies. (09 Feb 1998) |
| antibody induced lysis | <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis. See: complement lysis, natural killer cells. (09 Feb 1998) |
| antibody producing cell | <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell. (18 Nov 1997) |
| antibody-producing cells | Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise. (12 Dec 1998) |